aTYR PHARMA INC (ATYR) Institutional Ownership

Ownership Summary

aTYR PHARMA INC (NASDAQ:ATYR) currently has 76 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in aTYR PHARMA moved to 60.0% in December 2025, a shift down from the 72.0% reported for September 2025.
• The company experienced a -3.41% quarterly change in institutional shares held, alongside a decrease of 2.56% in total owners annually.
• A review of institutional activity for aTYR PHARMA shows 35 of 76 filers increasing their positions, while 24 reduced their stake, and 17 remained unchanged.
• Collectively, institutional investors decreased their stake in aTYR PHARMA to 55.01Mn shares as of December 2025, a change that is down by 1.94Mn shares quarter on quarter and up 140.72K shares year over year.
• With 14.70Mn shares, FMR LLC commands the largest institutional position in aTYR PHARMA as of December 31, 2025, equating to 16.04% of the company.
• Among the most significant buyers of aTYR PHARMA during December 2025 were GSA CAPITAL PARTNERS LLP (1.92Mn), TWO SIGMA ADVISERS, LP (841.35K), AQR CAPITAL MANAGEMENT LLC (769.82K), MORGAN STANLEY (692.67K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (638.07K).
• Leading sellers of aTYR PHARMA stock in December 2025 included UBS Group AG (2.88Mn), STATE STREET CORP (2.47Mn), VANGUARD GROUP INC (669.06K), ADAR1 Capital Management, LLC (431.62K), JANE STREET GROUP, LLC (400.44K).
• The top 10 institutional holders of aTYR PHARMA for the quarter ending December 2025 included FMR LLC (14.70Mn), FEDERATED HERMES, INC. (10.51Mn), BlackRock, Inc. (6.55Mn), VANGUARD GROUP INC (4.96Mn), GSA CAPITAL PARTNERS LLP (2.63Mn), GEODE CAPITAL MANAGEMENT, LLC (2.28Mn), STATE STREET CORP (1.72Mn), UBS Group AG (1.63Mn), MORGAN STANLEY (1.40Mn), Rosalind Advisors, Inc. (1.04Mn).